Redoxis AB has signed an agreement with Taconic Biosciences, Inc for service of characterization of cellular
composition of Taconic’s humanized immune system mice. This contract covers a recurrent service spanning over
“We are very excited about the collaboration with Taconic, which will beneficially impact Redoxis by adding value
and financial stability to our in vitro service platform” says Malin Hultqvist Hopkins, CEO, Redoxis.
For additional information please contact:
Malin Hultqvist Hopkins, CEO Redoxis AB, Email: firstname.lastname@example.org
Kelly Owen Grover, Director of Marketing Communications, Taconic Biosciences INC.